Search
Streptococcus pneumoniae type 15B capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB16717ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … * serotype 15B individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197).
Streptococcus pneumoniae type 23A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB19348ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … _ serotype 23A individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of _Corynebacterium diphtheriae_ strain C7 (β197).
Streptococcus pneumoniae type 5 capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10295ApprovedInvestigationalThe saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate. … serotype 5 individually conjugated to the CRM197 protein, a nontoxic variant of diphtheria toxin isolated from cultures of *Corynebacterium diphtheriae* strain C7 (β197).
Indinavir
go.drugbank.com/drugs/DB00224ApprovedInvestigationalA potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
Fospropofol
go.drugbank.com/drugs/DB06716ApprovedIllicitInvestigationalWithdrawnFospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act. … Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.
Abemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalOn September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed … Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.
Tolmetin
go.drugbank.com/drugs/DB00500ApprovedA non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin.
Revumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigationalIt was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … the majority of infant acute lymphoblastic leukemia cases.
Pacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigational[L40793] JAK2 signaling is important for hematopoiesis and proper immune functioning,[L40754] and while the precise role it plays in the pathogenesis of MF remains unclear, its clear association with MF … Pacritinib is an inhibitor of both wild-type and mutant (V617F) JAK2, as well as FMS-like tyrosine kinase 3 (FLT3), which was granted accelerated approval by the FDA in February 2022 for the treatment
Furazolidone
go.drugbank.com/drugs/DB00614InvestigationalVet approvedFurazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome